What is Leerink Partnrs’ Forecast for VYGR Q3 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, October 16th. Leerink Partnrs analyst L. Nsongo expects that the company will earn ($0.08) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.44) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.44) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.85) EPS and FY2028 earnings at ($0.22) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.20. The company had revenue of $29.58 million for the quarter, compared to the consensus estimate of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same period in the prior year, the firm posted ($0.51) EPS.

A number of other equities analysts also recently issued reports on VYGR. Wedbush dropped their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, October 11th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. Finally, Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $15.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $17.43.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $8.07 on Friday. Voyager Therapeutics has a 1 year low of $5.71 and a 1 year high of $11.72. The stock’s fifty day moving average price is $6.53 and its 200-day moving average price is $7.72. The company has a market cap of $438.96 million, a P/E ratio of -161.40 and a beta of 0.91.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its stake in Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after buying an additional 1,300 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares during the last quarter. SummerHaven Investment Management LLC grew its position in Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after purchasing an additional 1,921 shares during the last quarter. Hunter Perkins Capital Management LLC increased its stake in Voyager Therapeutics by 3.3% during the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after purchasing an additional 2,025 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Voyager Therapeutics by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after buying an additional 2,030 shares during the last quarter. 48.03% of the stock is owned by institutional investors.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.